He, Shanshan; Xiao, Jingbo; Dulcey, Andres E.; Lin, Billy; Rolt, Adam; Hu, Zongyi; Hu, Xin; Wang, Amy Q.; Xu, Xin; Southall, Noel; Ferrer, Marc; Zheng, Wei; Liang, T. Jake; Marugan, Juan J. published the article 《Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection》. Keywords: chlorcyclizine hepatitis antiviral virus infection.They researched the compound: 1-(Bis(4-chlorophenyl)methyl)piperazine( cas:27469-61-0 ).Safety of 1-(Bis(4-chlorophenyl)methyl)piperazine. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:27469-61-0) here.
Recently, we reported that chlorcyclizine (CCZ, Rac-2), an over-the-counter antihistamine piperazine drug, possesses in vitro and in vivo activity against hepatitis C virus. Here, we describe structure-activity relationship (SAR) efforts that resulted in the optimization of novel chlorcyclizine derivatives as anti-HCV agents. Several compounds exhibited EC50 values below 10 nM against HCV infection, cytotoxicity selectivity indexes above 2000, and showed improved in vivo pharmacokinetic properties. The optimized mols. can serve as lead preclin. candidates for the treatment of hepatitis C virus infection and as probes to study hepatitis C virus pathogenesis and host-virus interaction.
If you want to learn more about this compound(1-(Bis(4-chlorophenyl)methyl)piperazine)Safety of 1-(Bis(4-chlorophenyl)methyl)piperazine, you may wish to communicate with the author of the article,or consult the relevant literature related to this compound(27469-61-0).
Reference:
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics